艾地骨化醇治疗绝经后骨质疏松症中国专家建议  

Chinese expert recommendations on eldecalcitol treatment in post-menopausal osteoporosis

作　　者：姜艳[1] 岳华 李梅[1] 袁凌青[3] 刘建民[4] 徐又佳[5] 谢忠建[3] 林华[6] 金小岚 廖二元 章振林 夏维波[1] 中华医学会骨质疏松和骨矿盐疾病分会 JIANG Yan;YUE Hua;LI Mei;YUAN Ling-qing;LIU Jian-min;XU You-jia;XIE Zhong-jian;LIN Hua;JIN Xiao-lan;LIAO Er-yuan;ZHANG Zhen-lin;XIA Wei-bo(Chinese Society of Osteoporosis and Bone Mineral Research,Chinese Medical Association 1.Department of Endocrinology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;Department of Osteoporosis and Bone Disease,Shanghai Jiao Tong University School of Medicine Affiliated Sixth People s Hospital,Shanghai 200233,China;Department of Metabolism and Endocrinology,the Second Xiangya Hospital of Central South University,Changsha 410011,China;Department of Endocrine and Metabolic Diseases,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Department of Orthopaedics,the Second Affiliated Hospital of Soochow University,Suzhou 215004,Jiangsu,China;Department of Orthopedics,Affiliated Drum Tower Hospital,Medical School of Nanjing University,Nanjing 210008,China;Department of Endocrinology,Hospital of Chengdu University of Traditional Chinese Medicine,Traditional Chinese Medicine Hospital of Sichuan Province,Chengdu 610000,China;Department of Metabolism and Endocrinology,the First Affiliated Hospital,Hengyang Medical School,University of South China,Hengyang 421001,Hunan,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院内分泌科,北京100730 [2]上海交通大学医学院附属第六人民医院骨质疏松和骨病专科,上海200233 [3]中南大学湘雅二医院代谢与内分泌科,长沙410011 [4]上海交通大学医学院附属瑞金医院内分泌代谢病科,上海200025 [5]苏州大学附属第二医院骨科,江苏苏州215000 [6]南京大学医学院附属鼓楼医院骨科,南京210008 [7]成都中医药大学附属医院四川省中医医院内分泌科,成都610000 [8]南华大学衡阳医学院南华大学附属第一医院内分泌代谢科,湖南衡阳421001 [9]不详

出　　处：《中华骨质疏松和骨矿盐疾病杂志》2023年第3期189-196,共8页Chinese Journal Of Osteoporosis And Bone Mineral Research

摘　　要：艾地骨化醇是一种新型活性维生素D类似物,在1,25(OH)_(2)D_(3)基础上于2β位引入3-羟基丙氧基结构,与其他活性维生素D及类似物相比,具有更强的抑制骨吸收作用。临床证据显示艾地骨化醇治疗骨质疏松症具有良好的疗效和安全性。艾地骨化醇可增加骨质疏松症患者的骨密度,降低骨质疏松性椎体骨折和部分非椎体骨折风险,并且耐受性良好。艾地骨化醇在我国获批不久,临床经验仍需积累,中华医学会骨质疏松和骨矿盐疾病分会组织编写艾地骨化醇治疗绝经后骨质疏松症中国专家建议,以期为我国医务工作者合理使用艾地骨化醇提供帮助。Eldecalcitol[1a,25-dihydroxy-2β-(3-hydroxypropyloxy)vitamin D_(3)]is a novel active vitamin D analogue with stronger anti-resorptive effects than other analogues of vitamin D.Clinical studies have shown efficacy and safety of eldecalcitol in the treatment of osteoporosis.Eldecalcitol significantly increases the bone mineral density in osteoporotic patients,reduces the risk of osteoporotic vertebral and partial non-vertebral fractures,and is well tolerated.Since eldecalcitol has been approved in China recently,the accumulation of clinical experience is needed.Therefore,the current expert recommendations review the clinical evidence and provide guidance for clinician in China on eldecalcitol treatment in post-menopausal osteoporosis.

关 键 词：艾地骨化醇 绝经后骨质疏松症 活性维生素D类似物 专家建议 

分 类 号：R589.5[医药卫生—内分泌] R683[医药卫生—内科学]